Loading...
*  An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts -...
Individuals with AIDS frequently suffer central nervous system (CNS) problems that are characterized by cognitive, motor, and behavioral deficits, in a disorder known as AIDS dementia complex. Clinical experience suggests that its course is often progressive, going from initial symptoms to moderate or severe dementia within several months. Accumulating evidence now suggests that direct brain infection by the HIV virus is the likely cause of the AIDS dementia complex. Case reports suggest that therapy with AZT, which has been shown to be a strong inhibitor of HIV replication in vitro, may alleviate the AIDS dementia complex. This study will help define the natural history of the AIDS dementia complex in treated patients.. All patients receive AZT for 24 weeks. Patients are ...
https://clinicaltrials.gov/show/NCT00000709?order=24
*  What does aids dementia complex mean?
Definition of aids dementia complex in the Definitions.net dictionary. Meaning of aids dementia complex. What does aids dementia complex mean? Information and translations of aids dementia complex in the most comprehensive dictionary definitions resource on the web.
https://www.definitions.net/definition/aids%20dementia%20complex
*  A Multicenter Placebo-Controlled Double-Blind Trial to Evaluate Azidothymidine (AZT) Treatment of the AIDS Dementia Complex and...
HIV infection can result in impairment in the function of the brain and spinal cord, leading to disturbances in the ability to think clearly and in strength and coordination. This disorder, which has been called the AIDS dementia complex, may be due to a direct effect of HIV on the nervous system. It is known that AZT does get into the brain to some extent, where it may reduce growth of HIV. It is hoped that AZT will stabilize or improve the symptoms of the AIDS dementia complex.. The study is done in 2 stages. In Stage 1, patients are randomized to receive placebo or 1 of 2 doses of AZT. Stage 1 lasts for 4 months. In Stage 2, patients who were initially treated with placebo are randomized again and all patients receive AZT. Stage 2 lasts an additional 12 months, during which time there are periodic medical and neurologic evaluations. Before beginning treatment, all patients have a lumbar puncture and a ...
https://clinicaltrials.gov/show/NCT00000702?order=2
*  Plus it
OBJECTIVE--To assess the incidence of the AIDS dementia complex and the presence of HIV I p24 antigen in cerebrospinal fluid in relation to zidovudine treatment. DESIGN--Retrospective study of a consecutive series of patients with AIDS from 1982 to 1988. SETTING--An academic centre for AIDS. PATIENTS--196 Patients with AIDS and neurological symptoms examined from 1982 to 1988. INTERVENTIONS--Zidovudine treatment, which was introduced to The Netherlands on 1 May 1987 for patients with severe symptoms of HIV infection (Centers for Disease Control groups IVA, B, C, and D). MAIN OUTCOME MEASURES--Diagnosis of AIDS dementia complex and presence of HIV I p24 antigen in cerebrospinal fluid. RESULTS--The AIDS dementia complex was diagnosed in 40 of the 196 (20%) patients with AIDS. Thirty eight of ...
http://www.bmj.com/content/299/6703/819
*  AIDS Dementia Complex (ADC) - POZ
AIDS dementia complex (ADC), sometimes called HIV-associated dementia (HAD), is different than other types of AIDS-related illnesses.
https://www.poz.com/basics/hiv-basics/aids-dementia-complex-adc?utm_campaign=301_Redirect&utm_source=aidsmeds
*  Observational Study of HIV-associated Neurocognitive Disorder - Full Text View - ClinicalTrials.gov
It is estimated that over 1 million people in the United States have HIV infection. While HIV is treatable, there are still high rates of HIV-associated neurocognitive disorder (HAND). HAND is defined by low scores on memory testing. To meet the criteria for HAND, an HIV-infected individual has to have a low score on at least two different memory tests. It is estimated that 20-50% of people living with HIV have HAND. It is therefore still a common problem. While individuals with HAND typically improve on antiretroviral therapy for HIV, often this improvement is incomplete. Also, there are over 20 antiretroviral medications approved for HIV in the US. It is not clear if the specific choice of antiretroviral medication makes a difference in the improvement of HAND.. The investigators have designed a small preliminary study in which subjects with and without HAND who have never been on treatment for HIV or have been off treatment for at least 6 months are followed for the first 12 months after ...
https://clinicaltrials.gov/show/NCT01966094?order=274
*  Observational Study of HIV-associated Neurocognitive Disorder - Full Text View - ClinicalTrials.gov
It is estimated that over 1 million people in the United States have HIV infection. While HIV is treatable, there are still high rates of HIV-associated neurocognitive disorder (HAND). HAND is defined by low scores on memory testing. To meet the criteria for HAND, an HIV-infected individual has to have a low score on at least two different memory tests. It is estimated that 20-50% of people living with HIV have HAND. It is therefore still a common problem. While individuals with HAND typically improve on antiretroviral therapy for HIV, often this improvement is incomplete. Also, there are over 20 antiretroviral medications approved for HIV in the US. It is not clear if the specific choice of antiretroviral medication makes a difference in the improvement of HAND.. The investigators have designed a small preliminary study in which subjects with and without HAND who have never been on treatment for HIV or have been off treatment for at least 6 months are followed for the first 12 months after ...
https://clinicaltrials.gov/show/NCT01966094?order=289
*  Search of: HIV/AIDS AND neuroAIDS OR HIV/AIDS neuropathy OR polyneuropathy OR AIDS dementia complex OR AIDS neuropathy OR HIV...
23 Studies found for: HIV/AIDS AND neuroAIDS OR HIV/AIDS neuropathy OR polyneuropathy OR AIDS dementia complex OR AIDS neuropathy OR HIV neuropathy OR HIV-1 cognitive and motor complex OR AIDS-related primary CNS lymphoma , Recruiting, Not yet recruiting, Available Studies , NIH ...
https://clinicaltrials.gov/ct2/results?term=HIV%2FAIDS+AND+neuroAIDS+OR+HIV%2FAIDS+neuropathy+OR+polyneuropathy+OR+AIDS+dementia+complex+OR+AIDS+neuropathy+OR+HIV+neuropathy+OR+HIV-1+cognitive+and+motor+complex+OR+AIDS-related+primary+CNS+lymphoma&recr=Open&no_unk=Y&fund=0&show_flds=Y
*  A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC) - Full Text...
The signs and symptoms of the AIDS Dementia Complex can be alleviated by zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, particularly bone marrow suppression. The efficacy of ZDV appears to decrease during the second and third years of therapy. It is not known whether this reflects cumulative toxicity. In addition, the efficacy of other antiretroviral agents remains uncertain. Hence, adjunctive therapy for cognitive and motor symptoms of AIDS is important.. Patients will be randomized to one of the following 2 arms:. Arm 1 receives memantine plus concurrent antiretroviral therapy; Arm 2 receives placebo plus concurrent antiretroviral therapy. The initial dose of memantine is increased each week for the next 3 weeks, unless a maximum tolerated dose is reached. Following a 16-week evaluation period there is a 4-week washout prior to re-assessment. After the washout period, all patients, including those ...
https://clinicaltrials.gov/show/NCT00000867?order=132
*  A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC) - Full Text...
The signs and symptoms of the AIDS Dementia Complex can be alleviated by zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, particularly bone marrow suppression. The efficacy of ZDV appears to decrease during the second and third years of therapy. It is not known whether this reflects cumulative toxicity. In addition, the efficacy of other antiretroviral agents remains uncertain. Hence, adjunctive therapy for cognitive and motor symptoms of AIDS is important.. Patients will be randomized to one of the following 2 arms:. Arm 1 receives memantine plus concurrent antiretroviral therapy; Arm 2 receives placebo plus concurrent antiretroviral therapy. The initial dose of memantine is increased each week for the next 3 weeks, unless a maximum tolerated dose is reached. Following a 16-week evaluation period there is a 4-week washout prior to re-assessment. After the washout period, all patients, including those ...
https://clinicaltrials.gov/show/NCT00000867?order=134
*  A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC) - Full Text...
The signs and symptoms of the AIDS Dementia Complex can be alleviated by zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, particularly bone marrow suppression. The efficacy of ZDV appears to decrease during the second and third years of therapy. It is not known whether this reflects cumulative toxicity. In addition, the efficacy of other antiretroviral agents remains uncertain. Hence, adjunctive therapy for cognitive and motor symptoms of AIDS is important.. Patients will be randomized to one of the following 2 arms:. Arm 1 receives memantine plus concurrent antiretroviral therapy; Arm 2 receives placebo plus concurrent antiretroviral therapy. The initial dose of memantine is increased each week for the next 3 weeks, unless a maximum tolerated dose is reached. Following a 16-week evaluation period there is a 4-week washout prior to re-assessment. After the washout period, all patients, including those ...
https://clinicaltrials.gov/show/NCT00000867?order=137
*  A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC) - Full Text...
The signs and symptoms of the AIDS Dementia Complex can be alleviated by zidovudine (ZDV). However, ZDV therapy has been associated with significant toxicities, particularly bone marrow suppression. The efficacy of ZDV appears to decrease during the second and third years of therapy. It is not known whether this reflects cumulative toxicity. In addition, the efficacy of other antiretroviral agents remains uncertain. Hence, adjunctive therapy for cognitive and motor symptoms of AIDS is important.. Patients will be randomized to one of the following 2 arms:. Arm 1 receives memantine plus concurrent antiretroviral therapy; Arm 2 receives placebo plus concurrent antiretroviral therapy. The initial dose of memantine is increased each week for the next 3 weeks, unless a maximum tolerated dose is reached. Following a 16-week evaluation period there is a 4-week washout prior to re-assessment. After the washout period, all patients, including those ...
https://clinicaltrials.gov/show/NCT00000867?order=140
*  DMOZ - Health: Conditions and Diseases: Neurological Disorders: Dementia: AIDS Dementia Complex
The AIDS dementia complex is a brain disorder that occurs in people with AIDS (HIV infection) that causes the loss of cognitive capacity, affecting the ability to function in a social or occupational setting.
http://dmoztools.net/Health/Conditions_and_Diseases/Neurological_Disorders/Dementia/AIDS_Dementia_Complex/
*  AIDS Dementia Complex | Oak Hill Hospital | Brooksville, FL
Learn more about AIDS Dementia Complex at Oak Hill Hospital DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
https://oakhillhospital.com/hl/?/630076/&com.dotmarketing.htmlpage.language=1
*  AIDS Dementia Complex | Sunrise Hospital
Learn more about AIDS Dementia Complex at Sunrise Hospital & Medical Center DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
https://sunrisehospital.com/hl/?/630076/HIV-associated-dementia-complex&com.dotmarketing.htmlpage.language=1
*  AIDS Dementia Complex | TriStar Southern Hills
Learn more about AIDS Dementia Complex at TriStar Southern Hills DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision ...
http://tristarsouthernhills.com/hl/?/630076/AIDS-related-dementia
*  HIV-associated neurocognitive disorders: is there a hidden e... : AIDS
The neurocognitive disorders associated with HIV (HAND) remain among the most common clinical disorders encountered in people infected with HIV, even in an era in which potent antiretroviral therapy is widely deployed. HAND is currently considered to encompass a hierarchy of progressively more severe patterns of central nervous system (CNS) involvement ranging from asymptomatic neurocognitive impairment (ANI), to minor neurocognitive disorder (MND), to the more severe HIV-associated dementia (HAD) [1]. With the improved survival of individuals treated with antiretrovirals, comorbid conditions have become increasingly salient, including particularly coinfection with hepatitis C and the effects of aging. Treatment guidelines for preferred initial antiretroviral regimens and for second or salvage regimens are essentially silent on the approach to HAND. For example, HIV-nephropathy is one indication for initiation of HAART, yet inexplicably HAND is not, unless it is severe enough to manifest as ...
https://journals.lww.com/aidsonline/Fulltext/2010/06010/HIV_associated_neurocognitive_disorders__is_there.17.aspx
*  Aids dementia scale - Answers on HealthTap
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Uhrich on aids dementia scale: Can be a symptom of dementia of any kind when combined with physical problems such as hearing and vision loss. for topic: Aids Dementia Scale
https://www.healthtap.com/topics/aids-dementia-scale
*  Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders - Full Text View - ClinicalTrials.gov
The continued existence of cognitive dysfunction in HIV infected individuals in the era of effective antiretroviral therapy may be, in part, secondary to the failure of current antiretroviral regimens to eradicate the pool of HIV-infected and activated monocytes within the bloodstream. Trafficking of such HIV infected and activated blood monocytes into the brain parenchyma is believed to introduce HIV into the brain and precipitate immune activation and inflammation, ultimately leading to neuronal degeneration.. Ferumoxytol is an ultrasmall superparamagnetic iron-oxide (USPIO), which is FDA-approved for intravenous iron-replacement therapy in anemic patients with chronic kidney disease. The paramagnetic properties of ferumoxytol also allow it to be used as a MRI contrast agent. Ferumoxytol is avidly taken up by circulating monocytes and reactive astrocytes, microglia, and dendritic cells within the brain, making it potentially a novel biomarker for HIV-associated cognitive impairment given the ...
https://clinicaltrials.gov/ct2/show/NCT01665846?term=%22+July+25%2C++2012%22%3A%22+August+24%2C++2012%22%5BFIRST-RECEIVED-DATE%5DAND+HIV%5BCONDITION%5D&rank=8
*  AIDS dementia: overlay -- Slice #10
Tour 1: Next/Previous/Start: These images show typical findings in AIDS dementia: patchy hypoperfusion with a multifocal distribution which tends to be seen prominently in the frontal lobes. Compare with normal. Defects in cerebral perfusion have been previously reported in HIV positive individuals by single photon emission computed tomography (SPECT)[Masdeu, 1989 ][Pascal, 1991 ][Pohl, 1988 ][Holman, 1992 ][Schielke, 1990]. The anatomic and clinical significance of these findings, however, has remained uncertain. Because previous studies have shown that AIDS dementia complex (ADC) is associated with both functional defects and structural evidence of brain volume loss, we spatially matched (registered) the functional and structural data to assess the extent to which observed perfusion defects were "real", that is, represented low tracer uptake from structurally normal brain. The image datasets shown here are sampled along ...
http://www.med.harvard.edu/AANLIB/cases/case14/mr1-tc1/010.html
*  A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV - Full Text...
Inclusion Criteria:. Men and women 18 years of age or older and less than 65 years of age.. Able to read and understand English.. HIV infected on stable ART regimen for 5 months or greater, and not likely to change regimen for the duration of the study.. Significant dementia but able to give consent (International HIV Dementia Scale score ,10).. Significant cognitive slowing on screening, defined as 1 SD below normal (t-score ,60) on the Conner's CPT-II reaction time test.. Beck Depression Inventory score ,16.. Documented HIV-1 RNA PCR ,50 copies/mL and documented CD4 count ,200 within 3 months of entry visit.. Baseline CBC and chemistry panel Grade 1 or normal.. For females of reproductive potential (women who have not been post-menopausal for at least 24 consecutive months, i.e., who have had menses within 24 months prior to study entry), or women who have not undergone surgical sterilization, specifically hysterectomy or bilateral oophorectomy or tubal ligation) will ...
https://clinicaltrials.gov/ct2/show/study/NCT01599975?view=record
*  AIDS Neurological Center
The mission of the AIDS Neurological Center is to conduct research and provide clinical support on HIV-associated neurocognitive disorders. The Center investigators conduct both clinical and basic neuroscience research on the neurological and neuropsychological aspects of HIV and AIDS. The Center participates in and supports clinical trials with a neurological focus in the UNC AIDS Clinical Trials Unit locally and the AIDS Clinical Trials Group in the United States and internationally. Through the clinical component, the Center provides clinical consultation and evaluation for HIV and AIDS related neurological and neuropsychological disorders. The Center has an active basic neuroscience research program focused on the pathogenesis of HIV-associated neurocognitive disorders.. ...
http://www.med.unc.edu/neurology/divisions/neuroAIDS
*  Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder
AIDS Research and Treatment is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focused on all aspects of HIV and AIDS, from the molecular basis of disease to translational and clinical research. In addition, articles relating to prevention, education, and behavior change will be considered.
https://www.hindawi.com/journals/art/2012/953678/
*  HIV and Your Brain (HIV-Associated Neurocognitive Disorder) - POZ
In the mid to late 1980s, nearly half of all people with HIV eventually developed debilitating dementia or a serious brain-related infection.
https://www.poz.com/basics/hiv-basics/hiv-brain-hivassociated-neurocognitive-disorder
*  A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex - Full Text View - ClinicalTrials.gov
In this open-label, multicenter, multinational study, ZDV is replaced with d4T in ZDV-containing regimens, or d4T is added to non-ZDV-containing regimens in 20 patients experiencing ADC. Patients are defined as having failed treatment if they progress by one ADC stage on the MSK (Memorial Sloan Kettering) rating scale on study (i.e., from Stage 1 to 2 or Stage 2 to 3). Patients are evaluated on a weekly basis until the dementia deterioration is confirmed to be caused by HIV-1. The effect of d4T-containing regimens is assessed for the following parameters: neurological status, survival, AIDS-defining conditions, CSF (cerebrospinal fluid) and plasma viral load, CSF and blood immunological markers, blood CD4 cell counts, and viral resistance. This study also assesses the pharmacokinetics of d4T in the CSF and in the blood ...
https://clinicaltrials.gov/ct2/show/study/NCT00002246?view=results